Avacta Group Appoints David Liebowitz as Chief Medical Officer and Yulii Bogatyrenko as Advisor.

Avacta Group has appointed David Liebowitz as Chief Medical Officer to lead the company's clinical strategy and Yulii Bogatyrenko as an advisor in business development. Liebowitz has over 30 years of experience in academia and industry, contributing to the filing of 25 Investigational New Drug applications. Bogatyrenko will strengthen the company's business development strategy.

Avacta Group plc (AIM: AVCT), a life sciences company focused on developing innovative, targeted oncology drugs, has appointed David Liebowitz as Chief Medical Officer (CMO) and Yulii Bogatyrenko as an advisor in business development. These appointments come at a pivotal time for Avacta, as the company continues to advance its pipeline of targeted cancer therapies.

Dr. David Liebowitz, who brings over 30 years of experience in academia and industry, will lead Avacta's clinical strategy and execution. He has contributed to the successful filing of more than 25 Investigational New Drug (IND) applications and has a proven track record of advancing innovative therapies into the clinic. Dr. Liebowitz joins Avacta from Inovio Pharmaceuticals (Nasdaq: INO), where he served as Senior Vice President of early-stage clinical development, overseeing the clinical strategy for DNA-based vaccines and immunotherapies. Prior to Inovio, he held senior roles at Xencor, Vaxart, and Amgen, with a consistent focus on oncology, immunotherapy, and translational science [1].

Yulii Bogatyrenko, a Principal at Biopharma C&I, will strengthen Avacta's business development strategy. With extensive experience in business development and commercial strategy, Mr. Bogatyrenko has led multiple global commercial drug launches and numerous industry partnerships at leading pharmaceutical organizations such as Pfizer/Wyeth, Bayer Healthcare, and Teva Specialty Pharmaceuticals [1].

Christina Coughlin, MD, PhD, CEO of Avacta, commented, "We are thrilled to welcome David and Yulii at this pivotal time for Avacta. David’s deep expertise in oncology, coupled with a successful track record of advancing innovative therapies into the clinic, will be instrumental as we continue to execute on our clinical development strategy and progress our pre|CISION™ platform and pipeline of targeted cancer therapies. Yulii’s deep experience across commercial strategy, global drug launches, and industry partnerships at leading pharma organizations will be invaluable as we advance our pipeline and corporate growth strategy. We look forward to benefiting from their insights and strategic perspective as we remain focused on driving value for both patients and shareholders."

Avacta's pre|CISION® platform is a proprietary warhead delivery system designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. The company's innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates [2].

For further information from Avacta Group plc, please contact Michael Vinegrad, Group Communications Director at https://avacta.com/.

References:
[1] https://www.globenewswire.com/news-release/2025/07/01/3108206/0/en/Avacta-Appoints-David-Liebowitz-M-D-Ph-D-as-Chief-Medical-Officer-and-Yulii-Bogatyrenko-as-Advisor-in-Business-Development.html
[2] https://www.avacta.com/